UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                          ----------------------------

                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of report (Date of earliest event reported): October 10, 2005

                           Critical Therapeutics, Inc.
               (Exact Name of Registrant as Specified in Charter)

         Delaware                     000-50767                  04-3523569
(State or Other Jurisdiction         (Commission               (IRS Employer
      of Incorporation)              File Number)            Identification No.)


   60 Westview Street, Lexington, Massachusetts                     02421
    (Address of Principal Executive Offices)                      (Zip Code)

       Registrant's telephone number, including area code: (781) 402-5700

                                 Not applicable
          (Former Name or Former Address, if Changed Since Last Report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_|  Written communications pursuant to Rule 425 under the Securities Act
          (17 CFR 230.425)

     |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
          CFR 240.14a-12)

     |_|  Pre-commencement communications pursuant to Rule 14d-2(b) under the
          Exchange Act (17 CFR 240.14d-2(b))

     |_|  Pre-commencement communications pursuant to Rule 13e-4(c) under the
          Exchange Act (17 CFR 240.13e-4(c))




Item 8.01. Other Events.

     On October 10, 2005, Critical Therapeutics, Inc. (the "Company") issued a
press release announcing details of the commercial launch and price of ZYFLO(R)
(zileuton tablets), which is indicated for the prevention and chronic treatment
of asthma in patients 12 years of age and older. The Company also announced
details regarding the Company's Patient Assistance Program. The full text of the
Company's press release regarding the announcement is filed as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

      (d)  Exhibits.

           See Exhibit Index attached hereto.




                                    SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



Date: October 10, 2005                  CRITICAL THERAPEUTICS, INC.
                             
                                        By: /s/ Frank E. Thomas
                                            ------------------------------------
                                            Frank E. Thomas
                                            Chief Financial Officer, Senior Vice
                                            President of Finance and Treasurer




                                  EXHIBIT INDEX

Exhibit No.          Description
-----------          -----------

99.1                 Press Release dated October 10, 2005.